Clinical reversal of multidrug resistance

Stem Cells

Volumn 14, Issue 1, 1996, Pages 56-63

  Bates, Susan E ^a   Wilson, Wyndham H ^a   Fojo, Antonio T ^a   Alvarez, Manuel ^a   Zhan, Zhirong ^a   Regis, Joanna ^a   Robey, Rob ^a   Hose, Curtis ^a   Monks, Anne ^a   Kang, Yoon Koo ^a   Chabner, Bruce ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antagonist; Chemotherapy; Lymphoma; Multidrug resistance; P glycoprotein; Verapamil

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; PREDNISONE; VERAPAMIL; VINCRISTINE;

CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; HEART BLOCK; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 9044232862     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140056     Document Type: Review

References (31)

1. Harrison DJ. Molecular mechanisms of drug resistance in tumors. J Pathol 1995;175:7-12.
2. Morrow CS, Cowan KH. Antineoplastic drug resistance and breast cancer. Annals NY Acad Sci 1993;698:289-312.
3. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-1393.
4. Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of mouse mdr-1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502
5. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-2222.
6. Present CA, Kennedy PS, Wiseman C et al. Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 1986;9:355-357.
7. Ozols RF, O'Dwyer PJ, Hamilton TC. Clinical reversal of drug resistance in ovarian cancer. Gynecol Oncol 1993;51:90-96.
8. Miller TP, Grogan TM, Dalton WS et al. P-glycoprotein expression in malignant lymphomas and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24
9. Isonishi S, Kirmani S, Kim S et al. Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. J Natl Cancer Inst 1991;83:621-626.
10. Philip PA, Joel S, Monkman SC et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 1992;65:267-270.
11. Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-259.
12. Yahanda AM, Adler KM, Fisher GA et al. A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-1634.
13. Marie JP, Bastie JN, Coloma F et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993;7:821-824.
14. Samuels BL, Mick R, Vogelzang NJ et al. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 1993;54:421-429.
15. List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-1660.
16. Bates SE, Meadows B, Goldspiel BR et al. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother Pharmacol 1995;35:457-463.
17. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-1642.
18. Kerr DJ, Graham J, Cummings J et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-242.
19. Wilson WH, Bates SE, Fojo AT et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
20. Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem Pharmacol 1990;39:787-792.
21. Mickisch GH, Merlino GT, Aiken PM et al. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. J Urol 1991;146:447-453.
22. Wilson WH, Jamis-Dow C, Bryant G et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995;13:1985-1994.
23. Wilson WH, Bryant G, Bates SE et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993,11:1573-1582.
24. Kang YK, Zhan Z, Regis J et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995;86:1515-1524.
25. Murphy LD, Herzog CE, Rudick JB et al. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochem 1990;29:10351-10356.
26. Alvarez M, Paull K, Monks A et al. Expression of mdr-1/P-glycoprotein in the cell lines of the NCI anticancer drug screen program as a tool to identify novel P-glycoprotein substrates and antagonists. J Clin Invest 1995;95:2205-2214.
27. Lai G-M, Chen Y-N, Mickley LA et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703.
28. Salmon SE, Dalton WS, Grogan TM et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
29. Piwnica-Worms D, Chiu ML, Budding M et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
30. Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-766.
31. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990;82:1107-1112.